Analysts Set Expectations for Sanofi FY2024 Earnings

Sanofi (NASDAQ:SNY) – Equities researchers at Leerink Partnrs issued their FY2024 earnings estimates for Sanofi in a report issued on Monday, January 27th. Leerink Partnrs analyst D. Risinger forecasts that the company will post earnings per share of $3.77 for the year. The consensus estimate for Sanofi’s current full-year earnings is $3.82 per share. Leerink Partnrs also issued estimates for Sanofi’s Q4 2024 earnings at $0.74 EPS, Q1 2025 earnings at $0.75 EPS, Q2 2025 earnings at $0.84 EPS, FY2025 earnings at $4.06 EPS, FY2026 earnings at $4.57 EPS, FY2027 earnings at $4.76 EPS and FY2028 earnings at $5.39 EPS.

Separately, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th.

Sanofi Price Performance

NASDAQ SNY opened at $52.37 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm has a market capitalization of $132.92 billion, a PE ratio of 26.72, a P/E/G ratio of 1.19 and a beta of 0.57. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The company’s 50 day simple moving average is $48.99 and its 200 day simple moving average is $52.22.

Institutional Investors Weigh In On Sanofi

Institutional investors and hedge funds have recently modified their holdings of the business. Synergy Asset Management LLC acquired a new position in Sanofi during the 4th quarter worth $25,000. McClarren Financial Advisors Inc. lifted its position in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after acquiring an additional 543 shares during the last quarter. Northwest Investment Counselors LLC acquired a new position in Sanofi during the 3rd quarter worth $29,000. Concord Wealth Partners lifted its position in Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after acquiring an additional 363 shares during the last quarter. Finally, Fortitude Family Office LLC lifted its position in Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after acquiring an additional 659 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.